Mental Health
News
FDA okays new indication for esketamine nasal spray
“Esketamine may offer clinicians a new way to provide support to patients quickly in the midst of an urgent depressive episode,” said Dr. Gerard...
Latest News
‘Staggering’ increase in COVID-linked depression, anxiety
“The problem is bigger than anyone imagined, making it clear how the pandemic is affecting people now,” said Paul Gionfriddo of Mental Health...
Latest News
Pandemic-related stress causing health issues in many Americans
Survey shows that almost two-thirds of Hispanics report sleep, eating, temper, and other adverse effects brought on worry.
Conference Coverage
Learn to anticipate, resolve difficult interactions with patients
Begin by recognizing the difficult situation and assessing how the patient, the environment, or you might be contributing to the problem, said Dr...
Mental Health Consult
No-suicide contracts: Can they work?
Dr. Caroline Roberts analyzes the literature on NSCs in this installment of Mental Health Consult.
Conference Coverage
Novel drug may lower agitation, aggression in multiple psychiatric disorders
The study “supports vafidemstat as an emerging therapeutic option to treat aggression-agitation,” said Dr. Roger Bullock.
Conference Coverage
Stress, COVID-19 contribute to mental health concerns in college students
In a spring survey of students published by Active Minds about COVID-19 and its impact on mental health, 91% of students reported having stress or...
Conference Coverage
No ‘tidal wave’ of new mental illness; pandemic exacerbates preexisting conditions
Overall, the results suggest that “we’ve not all been ‘in this together,’ as we heard in some of the media,” Dr. Daisy Fancourt said.
Commentary
Consider adverse childhood experiences during the pandemic
What is the treatment for your patient’s high ACE score?
Conference Coverage
ECT more effective for psychotic vs. nonpsychotic depression?
In one study, response rates to ECT were significantly higher for the patients with psychotic depression than for those with nonpsychotic...
From the Journals
Travel times to opioid addiction programs drive a lack of access to treatment
The average drive time to OTPs in the United States is 20.4 minutes, compared with a drive time of 4.5 minutes to pharmacies.